Testing NST-628 in adults with grade 4 glioma that came back
Official title: A Phase 0/1 Study of NST-628 in Recurrent Grade 4 Glioma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests a drug called NST-628 in adults whose grade 4 glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has returned.
Read our full plain-language summary
What the trial team says
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression who are scheduled for surgical resection. This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability, and anti-tumor activity of NST-628.
Key facts
- Registry number
- NCT07784985
- Stage of testing
- Early phase 1
- Conditions studied
- Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
Where it is running
This trial lists 1 site.
-
Arizona
- St. Joseph's Hospital and Medical Center (Phoenix)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.